A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses
Year: 2022
Type: article
Source: Blood
Authors: Tamer Othman, Christopher Ruel, Paul Frankel, Alexander A. Merleev, Guillaume Luxardi, Emanual Maverakis, Mehrdad Abedi, Raghuveer Ranganathan, Jasmine Zain, Lihua E Budde, Matthew Mei, Aaron S Rosenberg, Rasmus T Hoeg, Caitlin Costello, Francine M. Foss, Basem M. William, H. Kent Holland, Miguel Villalona-Calero, Elad Sharon, Joseph M Tuscano
Institutions: UC Davis Comprehensive Cancer Center, University of California, Davis, City Of Hope National Medical Center, University of Southern California, USC Norris Comprehensive Cancer Center, University of California San Diego, Moores Cancer Center, Yale Cancer Center, Yale University, The Ohio State University, Northside Hospital, National Cancer Institute
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310159959